Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Assess the Safety, Tolerability and How Single Ascending Doses of ABBV-859 Moves Through the Body of Healthy Adult Participants
Sponsor: AbbVie
Summary
The objective of this study is to assess the pharmacokinetic (PK), immunogenicity, safety, and tolerability of ABBV-859 after single ascending doses in healthy adult volunteers.
Official title: A First-in-Human, Phase 1, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of ABBV-859 After Single Ascending Doses in Healthy Adult Subjects
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
64
Start Date
2026-07-28
Completion Date
2027-02
Last Updated
2026-08-03
Healthy Volunteers
Yes
Conditions
Interventions
ABBV-859
Oral Tablet
Placebo for ABBV-859
Oral Tablet
ABBV-859
Intravenous (IV) Infusion
Placebo for ABBV-859
Intravenous (IV) Infusion
Locations (2)
CenExel ACT- Anaheim Clinical Trials /ID# 284382
Anaheim, California, United States
Acpru /Id# 284029
Grayslake, Illinois, United States